Wockhardt Ltd
Wockhardt Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #17 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Wockhardt Ltd Q2 FY27 key numbers
- Revenue
- Total income for the quarter increased from Rs. 803 crore to Rs. 980 crore year-on-year.
As stated in Wockhardt Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.
Based on Wockhardt Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30/09/2026 is Rs. EBITDA for the quarter ended Sept 30, 2026: Rs.
From Wockhardt Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended 30/09/2026 is Rs. 969 crore, up from Rs. 782 crore in the quarter ended 30/09/2025, indicating a year-on-year increase of Rs. 187 crore.
- Total income for the quarter increased from Rs. 803 crore to Rs. 980 crore year-on-year.
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Wockhardt Ltd said on order book & pipeline — free account, 30 seconds.
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹969 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- JFL Life (Q2 FY27)
This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea
- P & G Health Ltd (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's
- Akums Drugs (Q2 FY27)
Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma
- Sai Parenteral's (Q2 FY27)
Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Key investor presentation takeaways from Sai Parenterals Ltd's
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30/09/2026 is Rs. EBITDA for the quarter ended Sept 30, 2026: Rs.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 77.3 with a market cap of ₹30,818 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.